ConductScience.org, home

Paper38492132

Prophylaxis of hepatic encephalopathy: current and future drug targets.

Maharshi S and 1 other. Hepatol Int, 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Prophylaxis of hepatic encephalopathy: current and future drug targets. Papers, record 38492132. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38492132

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prophylaxis of hepatic encephalopathy: current and future drug targets.
PubMed
Journal
Hepatol Int
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
1.99, provisional
iCite
Revised in PubMed
2026-11-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maharshi SSudhir
2Sharma BCBarjesh Chander

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatic EncephalopathyMajor topic
LactuloseMajor topic
RifaximinMajor topic
Humans
Probiotics
Gastrointestinal Agents
Fecal Microbiota Transplantation
Liver Transplantation
Secondary Prevention
Amino Acids, Branched-Chain
Primary Prevention
Dipeptides

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07273734UDCA to Prevent Post-TIPS Hepatic EncephalopathyResults

Source ClinicalTrials.gov

Download CSV of trials

References96

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114730033TIPS-related hepatic encephalopathy: management options with novel endovascular techniques.Radiographics2004https://conductscience.org/library/papers/14730033PubMed
233768619Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.J Hepatobiliary Pancreat Sci2021https://conductscience.org/library/papers/33768619PubMed
318691193Probiotic yogurt for the treatment of minimal hepatic encephalopathy.Am J Gastroenterol2008https://conductscience.org/library/papers/18691193PubMed
423401201Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.Hepatology2013https://conductscience.org/library/papers/23401201PubMed
530706425L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.Drugs2019https://conductscience.org/library/papers/30706425PubMed
634629016Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands.J Med Econ2021https://conductscience.org/library/papers/34629016PubMed
723216382Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.J Gastroenterol Hepatol2013https://conductscience.org/library/papers/23216382PubMed
834169435Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.Dig Dis Sci2022https://conductscience.org/library/papers/34169435PubMed
928316761Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial.Middle East J Dig Dis2017https://conductscience.org/library/papers/28316761PubMed
1021310833Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.Am J Clin Nutr2011https://conductscience.org/library/papers/21310833PubMed
1135266571Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.Hepatology2022https://conductscience.org/library/papers/35266571PubMed
1223425082Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.J Gastroenterol Hepatol2013https://conductscience.org/library/papers/23425082PubMed
1323972578Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.Clin Ther2013https://conductscience.org/library/papers/23972578PubMed
1417245628Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.Dig Dis Sci2007https://conductscience.org/library/papers/17245628PubMed
1521057793
Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series.
Cardiovasc Intervent Radiol2011https://conductscience.org/library/papers/21057793PubMed
1629624860Hepatic encephalopathy: Diagnosis and management.Liver Int2018https://conductscience.org/library/papers/29624860PubMed
1723565181Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.PLoS One2013https://conductscience.org/library/papers/23565181PubMed
1822832139
Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience.
J Vasc Interv Radiol2012https://conductscience.org/library/papers/22832139PubMed
1911495040Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients.J Hepatol2001https://conductscience.org/library/papers/11495040PubMed
2017312051Endovascular shunt reduction in the management of transjugular portosystemic shunt-induced hepatic encephalopathy: preliminary experience with reduction stents and stent-grafts.AJR Am J Roentgenol2007https://conductscience.org/library/papers/17312051PubMed

See all 96 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42589578XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis.Int J Mol Sci2026https://conductscience.org/library/papers/42589578PubMed
42137345Serum metabolomics identifies GPC depletion in hepatic encephalopathy and its therapeutic potential for cognitive impairment.Front Pharmacol2026https://conductscience.org/library/papers/42137345PubMed
42003914Amino Acid Metabolism in Chronic Liver Disease: from Pathogenic Driver to Therapeutic Target.Int J Biol Sci2026https://conductscience.org/library/papers/42003914PubMed
41904644The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research.Ann Med2026https://conductscience.org/library/papers/41904644PubMed
41331614Advances in capsule-based fecal microbiota transplantation: clinical applications and innovations.J Transl Med2025https://conductscience.org/library/papers/41331614PubMed
41272855Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial.Trials2025https://conductscience.org/library/papers/41272855PubMed
40309228Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions.World J Gastroenterol2025https://conductscience.org/library/papers/40309228PubMed
40177203Smartphone-based Stroop Test, EncephalApp: What is the optimal cutoff for diagnosing minimal hepatic encephalopathy?World J Hepatol2025https://conductscience.org/library/papers/40177203PubMed

Download CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
URSODIOLCHEMBL1551Results1https://conductscience.org/library/drugs/CHEMBL1551ChEMBL
LACTULOSECHEMBL296306Results1https://conductscience.org/library/drugs/CHEMBL296306ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38492132

GET https://conductscience.org/api/papers/v1/38492132/references?page=2